Pursuing Next-Generation Therapies
Effective therapies are needed to treat inflammatory and fibrotic diseases. Even with recent advances, many people still have few treatment options and continue to experience symptoms and disease progression.
Our Expertise
Gilead is researching new treatments to help address the needs of people living with inflammatory and fibrotic diseases, including primary biliary cholangitis (PBC), inflammatory bowel disease, lupus and metabolic dysfunction-associated steatohepatitis (MASH).
Leveraging our network of partnerships and extensive expertise in immunology, we're advancing a range of programs to help address these chronic conditions and the toll they take on patients’ lives.
Advancing Options for Primary Biliary Cholangitis
PBC is a rare, chronic, autoimmune disease that primarily affects women and can cause liver damage and possible liver failure if left untreated. The disease currently has no cure. More than half of people diagnosed with the condition are asymptomatic, but the symptoms that commonly appear — such as pruritus, or chronic skin itching — are often invisible to others, debilitating and can severely affect health-related quality of life. The journey to a PBC diagnosis can be long and challenging, especially when for many, there are no signs of the disease that others can see.
There has been a lack of new and effective treatment options for PBC until recently, with nothing available that addresses both the symptoms of PBC, as well as disease progression. We are constantly striving to improve liver care and provide more options so patients don’t have to settle for a treatment that may not address symptoms that severely impact their health-related quality of life.
Rheumatology
Pulmonology
Dermatology
Hepatology
Gastroenterology
Our Scientific Approach
Chronic inflammatory and fibrotic diseases are often characterized by a vicious cycle of tissue damage, immune response and fibrosis (scarring) that leads to organ damage and disease progression over time. Our programs focus on disrupting that cycle through four different methods, which we call our BETR framework:
PIPELINE
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development and external collaborations.
Latest News
Some of the content on this page is not intended for users outside the U.S.